|
Jan 8
|
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
|
|
Jan 5
|
Does Harmony Biosciences Holdings, Inc. (HRMY) Have the Potential to Rally 32.19% as Wall Street Analysts Expect?
|
|
Jan 4
|
All You Need to Know About Harmony Biosciences Holdings, Inc. (HRMY) Rating Upgrade to Buy
|
|
Jan 4
|
HRMY or ACAD: Which Is the Better Value Stock Right Now?
|
|
Jan 3
|
HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
|
|
Jan 2
|
Why Harmony Biosciences Stock Got Slammed Today
|
|
Dec 7
|
HRMY or GMAB: Which Is the Better Value Stock Right Now?
|
|
Dec 7
|
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
|
|
Dec 5
|
16 Most Undervalued Small-Cap Stocks To Buy According To Hedge Funds
|
|
Dec 5
|
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
|
|
Nov 29
|
Wall Street Analysts Predict a 44.38% Upside in Harmony Biosciences Holdings, Inc. (HRMY): Here's What You Should Know
|
|
Sep 9
|
10 Biotech Stocks with Biggest Upside
|
|
Sep 7
|
Harmony Biosciences Holdings Inc (HRMY): A Deep Dive into Its Performance Potential
|
|
Sep 7
|
HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA
|
|
Aug 28
|
HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION
|